A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
TerSera Therapeutics LLC
University of Nebraska
SecuraBio
SecuraBio
University of California, San Francisco
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
University of California, Davis
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Gilead Sciences
M.D. Anderson Cancer Center
Pharmacyclics LLC.
University Health Network, Toronto
M.D. Anderson Cancer Center
Novartis
Mayo Clinic
Novartis
University of California, San Diego
National Cancer Institute (NCI)
SCRI Development Innovations, LLC
Massachusetts General Hospital
SCRI Development Innovations, LLC
GlaxoSmithKline
GlaxoSmithKline
Novartis
SCRI Development Innovations, LLC
Medical University of South Carolina
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
Pharmacyclics LLC.
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
Teva Branded Pharmaceutical Products R&D, Inc.